Joshua C Grieger
Overview
Explore the profile of Joshua C Grieger including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
17
Citations
1539
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Thampi P, Samulski R, Grieger J, Phillips J, McIlwraith C, Goodrich L
Front Vet Sci
. 2023 Jan;
9:1117776.
PMID: 36686173
[This corrects the article DOI: 10.3389/fvets.2022.962898.].
2.
Kim A, Duerr F, Phillips J, Samulski R, Grieger J, Goodrich L
Gene Ther
. 2022 Oct;
30(3-4):398-404.
PMID: 36261499
A formal screening of self-complementary adeno-associated virus (scAAV) vector serotypes in canine joint tissues has not been performed to date. Selecting appropriate serotypes is crucial for successful treatment due to...
3.
Thampi P, Samulski R, Grieger J, Phillips J, McIlwraith C, Goodrich L
Front Vet Sci
. 2022 Oct;
9:962898.
PMID: 36246316
With an intrinsically low ability for self-repair, articular cartilage injuries often progress to cartilage loss and joint degeneration resulting in osteoarthritis (OA). Osteoarthritis and the associated articular cartilage changes can...
4.
Clement N, Grieger J
Mol Ther Methods Clin Dev
. 2016 Mar;
3:16002.
PMID: 27014711
The ability to elicit robust and long-term transgene expression in vivo together with minimal immunogenicity and little to no toxicity are only a few features that make recombinant adeno-associated virus...
5.
Wang G, Evans C, Benson J, Hutt J, Seagrave J, Wilder J, et al.
Mol Ther Methods Clin Dev
. 2016 Jan;
3:15052.
PMID: 26817025
Interleukin-1 (IL-1) plays an important role in the pathophysiology of osteoarthritis (OA), and gene transfer of IL-1 receptor antagonist (IL-1Ra) holds promise for OA treatment. A preclinical safety and biodistribution...
6.
Grieger J, Soltys S, Samulski R
Mol Ther
. 2015 Oct;
24(2):287-297.
PMID: 26437810
Adeno-associated virus (AAV) has shown great promise as a gene therapy vector in multiple aspects of preclinical and clinical applications. Many developments including new serotypes as well as self-complementary vectors...
7.
Monahan P, Sun J, Gui T, Hu G, Hannah W, Wichlan D, et al.
Hum Gene Ther
. 2014 Nov;
26(2):69-81.
PMID: 25419787
Vector capsid dose-dependent inflammation of transduced liver has limited the ability of adeno-associated virus (AAV) factor IX (FIX) gene therapy vectors to reliably convert severe to mild hemophilia B in...
8.
Goodrich L, Phillips J, McIlwraith C, Foti S, Grieger J, Gray S, et al.
Mol Ther Nucleic Acids
. 2013 Feb;
2:e70.
PMID: 23385523
Osteoarthritis (OA) affects over 40 million people annually. We evaluated interleukin-1 receptor antagonist (IL-1ra) gene transfer in an equine model based on IL-1ra protein therapy which inhibits inflammation through blocking...
9.
Grieger J, Samulski R
Methods Enzymol
. 2012 Feb;
507:229-54.
PMID: 22365777
Adeno-associated virus (AAV) has emerged as an attractive vector for gene therapy. The benefits of using AAV for gene therapy include long-term gene expression, the inability to autonomously replicate without...
10.
Bowles D, McPhee S, Li C, Gray S, Samulski J, Camp A, et al.
Mol Ther
. 2011 Nov;
20(2):443-55.
PMID: 22068425
Efficient and widespread gene transfer is required for successful treatment of Duchenne muscular dystrophy (DMD). Here, we performed the first clinical trial using a chimeric adeno-associated virus (AAV) capsid variant...